Loreb-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastroesophageal reflux disease (GERD) and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting symptomatic relief and mucosal healing in acid-related conditions. The synergistic action of these two agents provides effective control of acid reflux symptoms, improves esophageal mucosal integrity, and facilitates gastric emptying, making Loreb-DSR suitable for patients with erosive esophagitis, non-erosive reflux disease, and functional dyspepsia. The capsule formulation ensures convenient oral administration with optimal bioavailability. Loreb-DSR should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. Regular monitoring is recommended to assess therapeutic efficacy and detect potential adverse effects.